Gotistobart Improved Survival in Lung Cancer Trial
Updated Phase 3 trial results showed significant survival gains for patients with metastatic squamous lung cancer.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you trust that new medical clinical trials demonstrate genuine health benefits for cancer patients?
Researchers presented new data from the phase 3 PRESERVE-003 trial showing that gotistobart outperformed docetaxel in patients with metastatic squamous non-small cell lung cancer. The drug achieved a median overall survival of 18.5 months compared to 10 months for the standard chemotherapy.
Why it matters
Docetaxel has historically provided limited benefit for patients whose cancer has progressed after initial therapy. These findings offer a potential new path for treatment in difficult cases where standard options are insufficient.
The PRESERVE-003 trial reported a hazard ratio of 0.56 for overall survival. Grade 3 or higher treatment-related adverse events were recorded in 44.4% of the gotistobart arm, compared to 48.8% for docetaxel.
The players
Guangdong Lung Cancer Institute
This medical research facility is associated with the investigators who conducted and presented the findings of the PRESERVE-003 trial.
The details
Gotistobart functions as an anti-CTLA-4 antibody that helps clear regulatory T cells from tumors while preserving the receptor from breakdown. The study, which included a 25.4-month median follow-up, identified no new safety signals or treatment-related deaths.
Timeline
September 21, 2026: Updated trial findings were presented.
The Big Picture
The PRESERVE-003 trial results follow the pattern of previous anti-CTLA-4 immunotherapy studies for advanced lung malignancies. This study updates the survival metrics and safety profile of immunotherapy treatments previously established by the trial.
Patients with metastatic squamous non-small cell lung cancer may eventually have access to a more effective therapy that demonstrates better survival outcomes than current standards. The results indicate that this immunotherapy may also present a manageable safety profile compared to traditional chemotherapy.
The takeaway
These findings suggest that targeting regulatory T cells could significantly extend survival in advanced lung cancer patients. Further monitoring will continue to clarify the long-term clinical utility of this specific immunotherapy regimen.
Further reading
Learn more about ongoing advancements in Cancer research and treatment options.
Source note: This article includes information reported by OncLive.
Live Poll
Do you trust that new medical clinical trials demonstrate genuine health benefits for cancer patients?
